20 research outputs found
Approaches to Assessing the Demand for Vocational Education
The article discusses the prospects for the development of regional systems of secondary vocational education (on the basis of basic general education) through the prism of assessing the demand for secondary vocational education and covering this level of education in the context of demography and competition from schools Keywords: secondary vocational education, demand for education, educational coverage, private educational organizations, regional education system
The Need for Regional Labor Markets for Mid-Level Specialists and the Priorities of Graduates of Secondary Vocational Education in Employment Issues
The article considers the problems of imbalance of supply and demand in regional labor markets, as well as the role of career guidance in choosing a profession. The article discloses the main management decisions for regulating reception targets, taking into account labor market requirements. The authors give examples of calculating the imbalance of supply and demand in personnel in regional labor markets using the example of the regionβs need for mid-level medical workers. The article considers the aspects of employment of graduates of professional educational organizations, including labor migration and international experience. As a result of the study, the authors identified and formulated the general laws of labor migration of graduates of professional educational organizations and solutions to reduce the outflow of labor resources from the region. Separately, the authors examined the employment of graduates of the SVE (secondary vocational education) system in Moscow and St. Petersburg. The article was completed within the framework of the topic of the State Task of the RANEPA N 11.5 βStudy of models for the transformation of regional systems of secondary vocational education and their need for resource supportβ for 2021
Science at Universities β the Development Driver or Privilege of the Selected Ones
The research article considers an influence of university research funding on the development of different kind of universities. During last 10β15 years a lot of strategic documents regarding development of science and higher education mention an importance of intensive grow on research in universities. They should transform to research centers instead of just education facilities, lead a scientific field in Russia. Presumably such additions in science management practices as new evaluation, stimulation and efficiency improvement instruments and mechanisms will increase an influence of R&D departments on whole university development. The main purpose of current article is to analyze trends in shifts of research funding indicators for universities of different profiles and for higher education sector in general; to compare research funding volume with public indicators of university development; to evaluate the impact of research in higher education to higher institution development indicators. During the study our group has analyzed connections between research funding indicators and individual R&D efficiency indicators at universities. The analysis is based on statistics from Federal State Statistics Service, and annual monitoring of university activities for the period 2014β2020, from Ministry of Education and Science of Russia. The result of the study shows an insignificant effect of university research funding volume to university development indicators; high government participance in higher institutions research development; significant irregularity and historical inertia in reorganization of universities to large scientific and education centers.ΠΠ°Π½Π½Π°Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠ°Ρ ΡΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠ·ΠΎΠ²ΡΠΊΠΎΠΉ Π½Π°ΡΠΊΠΈ Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π²ΡΠ·ΠΎΠ² ΡΠ°Π·Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ. Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ 10β15 Π»Π΅Ρ Π² ΡΡΡΠ°ΡΠ΅Π³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°Ρ
ΠΏΠΎ Π²ΠΎΠΏΡΠΎΡΠ°ΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π½Π°ΡΠΊΠΈ ΠΈ Π²ΡΡΡΠ΅Π³ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ, Π½Π°ΠΏΡΠΈΠΌΠ΅Ρ, Π² ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ΅ Β«ΠΠ°ΡΡΠ½ΠΎ-ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈΒ», ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΌ ΠΏΡΠΎΠ΅ΠΊΡΠ΅ Β«ΠΠ°ΡΠΊΠ° ΠΈ ΡΠ½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅ΡΡΒ», ΠΡΠΎΠ³ΡΠ°ΠΌΠΌΠ΅ ΡΡΡΠ°ΡΠ΅Π³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΠΊΠ°Π΄Π΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»ΠΈΠ΄Π΅ΡΡΡΠ²Π° ΠΈ Ρ. ΠΏ., Π² ΡΠ²Π½ΠΎΠΌ ΠΈ Π½Π΅ΡΠ²Π½ΠΎΠΌ Π²ΠΈΠ΄Π΅ ΡΠΎΡΠΌΡΠ»ΠΈΡΡΠ΅ΡΡΡ Π·Π°Π΄Π°ΡΠ° ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π²ΡΠ·Π°Ρ
, ΠΏΡΠ΅Π²ΡΠ°ΡΠ΅Π½ΠΈΡ Π²ΡΠ·ΠΎΠ² ΠΈΠ· ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΡΡ
Π² Π½Π°ΡΡΠ½ΠΎ-ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π½ΡΡΡ, Π·Π°Π½ΠΈΠΌΠ°ΡΡΠΈΠ΅ Π»ΠΈΠ΄ΠΈΡΡΡΡΠΈΠ΅ ΠΏΠΎΠ·ΠΈΡΠΈΠΈ Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΡΡΠ°Π½Ρ. ΠΡΠ΅Π΄ΠΏΠΎΠ»Π°Π³Π°Π΅ΡΡΡ, ΡΡΠΎ Π²Π²ΠΎΠ΄ΠΈΠΌΡΠ΅ Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ ΠΎΡΠ΅Π½ΠΊΠΈ, ΡΡΠΈΠΌΡΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΡΠ΄ΡΡ ΡΡΠΈΠ»ΠΈΠ²Π°ΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π²ΡΠ·ΠΎΠ²ΡΠΊΠΎΠΉ Π½Π°ΡΠΊΠΈ Π½Π° ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π²ΡΠ·ΠΎΠ². Π¦Π΅Π»Ρ Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΡΠ°ΡΡΠΈ β ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π²ΡΠ·Π°Ρ
ΡΠ°Π·Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ»Π΅ΠΉ ΠΈ Π² ΡΠ΅Π»ΠΎΠΌ Π² ΡΡΠ΅ΡΠ΅ Π²ΡΡΡΠ΅Π³ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ, ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΡΡ ΠΎΠ±ΡΠ΅ΠΌΡ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠ·ΠΎΠ²ΡΠΊΠΎΠΉ Π½Π°ΡΠΊΠΈ Ρ Π΄ΠΎΡΡΡΠΏΠ½ΡΠΌΠΈ Π΄Π°Π½Π½ΡΠΌΠΈ ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°Ρ
ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²ΡΠ·ΠΎΠ² ΠΈ ΠΎΡΠ΅Π½ΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π²ΡΡΡΠ΅ΠΉ ΡΠΊΠΎΠ»Π΅ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²ΡΠ·ΠΎΠ². Π Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈΡΡ ΡΠ²ΡΠ·ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π²ΡΠ·Π°Ρ
Ρ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎΡΡΠΈ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²ΡΠ·ΠΎΠ². ΠΠ»Ρ Π°Π½Π°Π»ΠΈΠ·Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ»ΡΠΆΠ±Ρ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠΈ, ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠ³ΠΎ ΠΠΈΠ½ΠΎΠ±ΡΠ½Π°ΡΠΊΠΈ Π ΠΎΡΡΠΈΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Π²ΡΠ·ΠΎΠ² Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 2014β2020 Π³Π³. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΎΠ±ΡΠ΅ΠΌΠΎΠ² ΡΠΈΠ½Π°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²ΡΠ·ΠΎΠ²ΡΠΊΠΎΠΉ Π½Π°ΡΠΊΠΈ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π²ΡΠ·ΠΎΠ², Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΡ ΡΠΎΠ»Ρ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π° Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π½Π°ΡΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² Π²ΡΡΡΠ΅ΠΉ ΡΠΊΠΎΠ»Π΅ ΠΈ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π½Π΅ΡΠ°Π²Π½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΡ ΠΈ ΠΈΡΡΠΎΡΠΈΡΠ΅ΡΠΊΡΡ ΠΈΠ½Π΅ΡΡΠΈΠΎΠ½Π½ΠΎΡΡΡ Π² ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΠΈ Π²ΡΠ·ΠΎΠ² ΠΊΠ°ΠΊ ΠΊΡΡΠΏΠ½ΡΡ
Π½Π°ΡΡΠ½ΠΎ-ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ΅Π½ΡΡΠΎΠ²
ΠΠ ΠΠΠΠΠ ΠΠ’ΠΠΠ¬ΠΠ«Π Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π« ΠΠ‘ΠΠΠΠ¬ΠΠΠΠΠΠΠ― Π€Π’ΠΠ ΠΠ€Π£Π Π Π ΠΠΠΠΠΠΠΠ¦ΠΠ Π‘ ΠΠ ΠΠΠΠ’ΠΠΠΠΠΠ Π ΠΠΠ‘ΠΠΠΠΠΠΠ’ΠΠΠΠ Π£ ΠΠΠ¦ΠΠΠΠ’ΠΠ Π‘ Π ΠΠ‘ΠΠ ΠΠ‘Π’Π ΠΠΠΠΠΠ«Π ΠΠΠΠΠ ΠΠΠ’ΠΠΠ¬ΠΠ«Π Π ΠΠΠΠ
Objective: to develop an effective, well-tolerated, convenient for outpatient care (without installing a subclavian catheter) three-component treatment regimen that includes ftorafur β an original oral fluoropyrimidine drug.Materials and methods. The study included 25 patients with disseminated colorectal cancer that have never received specific pharmacotherapy. We evaluated the efficacy and safety of a new first-line three-component treatment regimen with oxaliplatin + irinotecan + ftorafur. Patients in group 1 (n = 6) received this regimen for 3 weeks, whereas patients in group 2 (n = 19) received it for 2 weeks.Results. Only preliminary results of the study are currently available. Median time to progression and overall survival are not yet estimated. Three (50 %) patients from group 1 achieved partial regression of metastases; 3 patients from this group had long-term (β₯6 months) disease stabilization. Therapeutic effect (partial remission + long-term stabilization) was observed in all patients. Time without progression varied between 6 and 20 months. In group 2, therapeutic effect was estimated in 18 patients that received at least 2 courses of chemotherapy. Eight out of these 18 patients had partial response (2 of them underwent radical surgery); 8 patients had disease stabilization. Thus, 88.8 % of patients from group 2 responded to treatment. In the whole study population (both groups), response to treatment was achieved in 91 % of patients.Conclusion. Our preliminary results suggest that the combination of oxaliplatin, irinotecan and ftorafur is safe and has an acceptable toxicity profile; therefore, it can be used in weakened patients.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠ΄ΠΎΠ±Π½ΠΎΠ³ΠΎ Π΄Π»Ρ Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ (Π±Π΅Π· Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΡΡΡΠ°Π½ΠΎΠ²ΠΊΠΈ ΠΏΠΎΠ΄ΠΊΠ»ΡΡΠΈΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΡΡΠ°), Ρ
ΠΎΡΠΎΡΠΎ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΠ³ΠΎ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΡΠ΅Ρ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΠΆΠΈΠΌΠ°, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅Π³ΠΎ ΠΏΠ΅ΡΠΎΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΡΡΠΎΡΠΏΠΈΡΠΈΠΌΠΈΠ΄ΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ΄Π° ΡΡΠΎΡΠ°ΡΡΡ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ 25 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌ ΠΊΠΎΠ»ΠΎΡΠ΅ΠΊΡΠ°Π»ΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ, Π½Π΅ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΠ°Π½Π΅Π΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, Ρ ΠΊΠΎΡΠΎΡΡΡ
Π² 1-ΠΉ Π»ΠΈΠ½ΠΈΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΠ΅Π½Π΅Π½Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ΅Ρ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΠΆΠΈΠΌΠ° ΠΈΡΠΈΠ½ΠΎΡΠ΅ΠΊΠ°Π½ + ΠΎΠΊΡΠ°Π»ΠΈΠΏΠ»Π°ΡΠΈΠ½ + ΡΡΠΎΡΠ°ΡΡΡ. Π 1-ΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (n = 6) Π±ΡΠ» ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ 3-Π½Π΅Π΄Π΅Π»ΡΠ½ΡΠΉ ΡΠ΅ΠΆΠΈΠΌ Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π²ΠΎ 2-ΠΉ Π³ΡΡΠΏΠΏΠ΅ (n = 19) β 2-Π½Π΅Π΄Π΅Π»ΡΠ½ΡΠΉ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ΅Π΄ΠΈΠ°Π½Ρ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π΄ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π½Π΅ Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΡ. Π 1-ΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΠ°ΡΡΠΈΡΠ½Π°Ρ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΡ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΠ° Ρ 3 (50 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π΄Π»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ (β₯6 ΠΌΠ΅Ρ) ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Π΅ΡΠ΅ Ρ 3 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΠ΅ΡΠ΅Π±Π½ΡΠΉ ΡΡΡΠ΅ΠΊΡ (ΡΠ°ΡΡΠΈΡΠ½Π°Ρ ΡΠ΅ΠΌΠΈΡΡΠΈΡ + Π΄Π»ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ) ΠΎΡΠΌΠ΅ΡΠ΅Π½ Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². ΠΡΠ΅ΠΌΡ Π±Π΅Π· ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΎΡΡΠ°Π²Π»ΡΠ»ΠΎ ΠΎΡ 6 Π΄ΠΎ 20 ΠΌΠ΅Ρ. ΠΠΎ 2-ΠΉ Π³ΡΡΠΏΠΏΠ΅ ΡΡΡΠ΅ΠΊΡ ΠΎΡΠ΅Π½Π΅Π½ Ρ 18 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ 2 ΠΊΡΡΡΠ° Ρ
ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π£ 8 ΠΈΠ· 18 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΡΠΌΠ΅ΡΠ΅Π½ ΡΠ°ΡΡΠΈΡΠ½ΡΠΉ ΠΎΡΠ²Π΅Ρ (ΠΈΠ· Π½ΠΈΡ
2 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π±ΡΠ»ΠΈ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎ ΠΏΡΠΎΠΎΠΏΠ΅ΡΠΈΡΠΎΠ²Π°Π½Ρ), Ρ 8 Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π²ΠΎ 2-ΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΎΡΠ²Π΅Ρ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π΄ΠΎΡΡΠΈΠ³Π½ΡΡ Ρ 88,8 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π‘ΡΠΌΠΌΠ°ΡΠ½ΡΠΉ ΠΎΡΠ²Π΅Ρ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² ΠΎΠ±Π΅ΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΡΠΎΡΡΠ°Π²ΠΈΠ» 91 %.ΠΡΠ²ΠΎΠ΄Ρ. ΠΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΌΠΎΠ³ΡΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΡ ΠΎΠΊΡΠ°Π»ΠΈΠΏΠ»Π°ΡΠΈΠ½Π°, ΠΈΡΠΈΠ½ΠΎΡΠ΅ΠΊΠ°Π½Π° ΠΈ ΡΡΠΎΡΠ°ΡΡΡΠ° ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ, ΠΈΠΌΠ΅Π΅Ρ ΠΏΡΠΈΠ΅ΠΌΠ»Π΅ΠΌΡΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ ΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π° Ρ ΠΎΡΠ»Π°Π±Π»Π΅Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
Objective: to develop an effective, well-tolerated, convenient for outpatient care (without installing a subclavian catheter) three-component treatment regimen that includes ftorafur β an original oral fluoropyrimidine drug.Materials and methods. The study included 25 patients with disseminated colorectal cancer that have never received specific pharmacotherapy. We evaluated the efficacy and safety of a new first-line three-component treatment regimen with oxaliplatin + irinotecan + ftorafur. Patients in group 1 (n = 6) received this regimen for 3 weeks, whereas patients in group 2 (n = 19) received it for 2 weeks.Results. Only preliminary results of the study are currently available. Median time to progression and overall survival are not yet estimated. Three (50 %) patients from group 1 achieved partial regression of metastases; 3 patients from this group had long-term (β₯6 months) disease stabilization. Therapeutic effect (partial remission + long-term stabilization) was observed in all patients. Time without progression varied between 6 and 20 months. In group 2, therapeutic effect was estimated in 18 patients that received at least 2 courses of chemotherapy. Eight out of these 18 patients had partial response (2 of them underwent radical surgery); 8 patients had disease stabilization. Thus, 88.8 % of patients from group 2 responded to treatment. In the whole study population (both groups), response to treatment was achieved in 91 % of patients.Conclusion. Our preliminary results suggest that the combination of oxaliplatin, irinotecan and ftorafur is safe and has an acceptable toxicity profile; therefore, it can be used in weakened patients
Development of the repair service system in territorial and united generating companies after completion of industry restructuring processes
Strategy of the development of a power-equipment repair company under the conditions of a competitive market
SAFETY AND IMMUNOGENICITY OF A NATIONAL COMBINED VACCINE AGAINST PERTUSSIS, DIPHTHERIA, TETANUS, HEPATITIS B AND Hib-INFECTION, CONTAINING ACELLULAR PERTUSSIS COMPONENT, DURING IMMUNIZATION OF ADULTS
Aim. Study safety, reactogenicity and immunologic effectiveness of a national combined vaccine against diphtheria, pertussis (acellular component), tetanus, hepatitis B and Hib-infection during immunization of volunteers aged 18 - 60 years. Materials and methods. The study was carried out in accordance with ethical standards and requirements, regulated by Helsinki declaration and Good clinical practice (ICHGCP). In a simple non-randomized clinical trial 20 adult volunteers took part, the mean age of those was 46.9 years. Results. Registered post-vaccination reactions (both local and systemic) were mild and of moderate degree of severity, stopped independently after 2 - 3 days without administration of drug treatment. Postvaccinal complications were not noted. Parameters of general and biochemical analysis of blood, urine, IgE content in dynamics of immunization were within normal limits. A single administration of aAPDT-HepB+Hib to individuals aged 18 - 60 years resulted in development of antibodies against all the components of the preparation. Seroconversion factor fluctuated from 6.9 to 53.5. Conclusion. The results obtained allow to recommend the vaccine for evaluation of its safety, reactogenicity, immunologic and prophylaxis effectiveness in randomized clinical observation trials in children
National Projects and Improvement of Monitoring of their Implementation in the Sphere of Lifelong Vocational Training
This is a concept article proposing trends and methods to improve monitoring of national projects in terms of training personnel for professional development programs at all levels. The paper is based on analysing Russian and international methodologies and practices of education development monitoring. The problem of precise defining personnel development quantitative indicators within national projects implementation is significant both for universities as a part of management decision planning and for government structures, with an information database (correctly representing the process and results of implementing national projects) to be relied upon by the latter. The analysis of Russian federal statistic monitoring forms of personnel development has revealed a number of weaknesses which complicate regular monitoring of national projects implementation. The research has also shown examples of incorrect key indicators setting. The article mainly aims at proposing directions for personnel development methods in ongoing professional development education system according to national project purposes in this part. The article compares EUβs, OECDβs, USAβs, and Russian methodologies and basic monitoring techniques for personnel development. There are revealed their significant differences, advantages and disadvantages, including those used within cross-country comparisons. The analysis shows that foreign models of projects framework cannot be applied to operational monitoring of national projects implementation. The Russian system of federal statistical monitoring requires a certain modification, which can be implemented quite easily and can provide monitoring of national projects implementation in terms of professional development. The article proposes suggestions on improving the monitoring system of national projects implementation according to monitoring purposes. Besides, it can be a basis for future harmonization research for Russian and foreign methodologies of education monitoring. Universities may use the suggestions expressed in the paper for improving national projects implementation monitoring as a part of their management practice. It will allow them to estimate a status and efficiency of their contribution to national projects implementation. The newly proposed methods of national projects realization monitoring can be used by educational bodies and universities within personnel training and improving the system of lifelong vocational training. These methods may be of help when developing control national projects implementation monitoring and vocational training system monitoring in general or in its parts.Π Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΠΊΠΎΠ½ΡΠ΅ΠΏΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°ΡΡΠ΅ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΡΠ΅ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΈ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ ΠΈΡ
ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅Π΄Π»Π°Π³Π°ΡΡΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² Π² ΡΠ°ΡΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² ΠΏΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΡΠΌ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ°ΠΌ Π²ΡΠ΅Ρ
ΡΡΠΎΠ²Π½Π΅ΠΉ. ΠΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΊΠΎΡΡΠ΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² Π°ΠΊΡΡΠ°Π»ΡΠ½Π° ΠΊΠ°ΠΊ Π΄Π»Ρ Π²ΡΠ·ΠΎΠ² ΠΏΡΠΈ Π²ΡΡΠ°Π±ΠΎΡΠΊΠ΅ ΡΠΏΡΠ°Π²Π»Π΅Π½ΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΏΠΎ ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ ΠΈΡ
ΡΠ°Π·Π²ΠΈΡΠΈΡ Π² ΡΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠΈ Ρ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π»ΡΠΌΠΈ ΠΈ ΡΡΡΠ°ΡΠ΅Π³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π΄Π°ΡΠ°ΠΌΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΡΠ°Π½Ρ, ΡΠ°ΠΊ ΠΈ Π΄Π»Ρ ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ. ΠΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ ΠΏΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠΉ Π΄ΠΎΠ»ΠΆΠ½Ρ ΠΎΠΏΠΈΡΠ°ΡΡΡΡ Π½Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΡΡ Π±Π°Π·Ρ, ΠΊΠΎΡΡΠ΅ΠΊΡΠ½ΠΎ ΠΎΡΠΎΠ±ΡΠ°ΠΆΠ°ΡΡΡΡ Ρ
ΠΎΠ΄ ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ². ΠΠ½Π°Π»ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π² Π ΠΎΡΡΠΈΠΈ ΡΠΎΡΠΌ ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΎΠ±Π½Π°ΡΡΠΆΠΈΡΡ ΡΡΠ΄ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΎΠ², Π·Π°ΡΡΡΠ΄Π½ΡΡΡΠΈΡ
ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ², ΡΠ°ΠΊΠΆΠ΅ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΏΡΠΈΠΌΠ΅ΡΡ Π½Π΅ΠΊΠΎΡΡΠ΅ΠΊΡΠ½ΠΎΠ³ΠΎ Π·Π°Π΄Π°Π½ΠΈΡ ΡΠ΅Π»Π΅Π²ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² Π² Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠ°Ρ
. ΠΠΌΠ΅Π½Π½ΠΎ ΡΡΠΎ ΠΏΠΎΡΠ»ΡΠΆΠΈΠ»ΠΎ ΠΏΡΠΈΡΠΈΠ½ΠΎΠΉ Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΡΠ°ΡΡΠΈ, ΡΠ΅Π»Ρ ΠΊΠΎΡΠΎΡΠΎΠΉ β ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠΈΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² Π² ΡΠΈΡΡΠ΅ΠΌΠ΅ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² Π² ΡΡΠΎΠΉ ΡΠ°ΡΡΠΈ. Π ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΈ ΡΠΎΠΏΠΎΡΡΠ°Π²Π»ΡΡΡΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΠ΅ Π² ΠΠ‘, ΠΠΠ‘Π , Π‘Π¨Π, Π ΠΎΡΡΠΈΠΈ, Π²ΡΡΠ²Π»ΡΡΡΡΡ ΠΈΡ
ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ, ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΈ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π² ΠΌΠ΅ΠΆΡΡΡΠ°Π½ΠΎΠ²ΡΡ
ΡΡΠ°Π²Π½Π΅Π½ΠΈΡΡ
. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ Π΄Π»Ρ ΡΠ΅Π»Π΅ΠΉ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ Π² ΡΠΈΠ»Ρ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π½Π΅ ΠΌΠΎΠ³ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ Π΄Π»Ρ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π°, Π° ΡΠΎΡΡΠΈΠΉΡΠΊΠ°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΡΠ΅Π±ΡΠ΅Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠΉ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ, ΠΊΠΎΡΠΎΡΠ°Ρ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π»Π΅Π³ΠΊΠΎ ΡΠ΅Π°Π»ΠΈΠ·ΡΠ΅ΠΌΠ° ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΡΡ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³ ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² Π² ΡΠ°ΡΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² Ρ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ Π² ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΏΠΎ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΡΠΈΡΡΠ΅ΠΌΡ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² ΠΌΠΎΠ³ΡΡ Π² ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅ΠΌ Π΄Π΅ΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°ΡΡΡΡ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΡΠ΅Π»ΡΠΌΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΡΠ»ΡΠΆΠΈΡΡ ΠΎΡΠ½ΠΎΠ²ΠΎΠΉ Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π² ΡΡΠ΅ΡΠ΅ Π³Π°ΡΠΌΠΎΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΈ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ. Π‘ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ ΡΠ½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅ΡΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅Π½Π΅Π΄ΠΆΠΌΠ΅Π½ΡΠ° ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅ΠΌΡΠ΅ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² ΠΌΠΎΠ³ΡΡ Π² ΠΈΠ½ΠΈΡΠΈΠ°ΡΠΈΠ²Π½ΠΎΠΌ ΠΏΠΎΡΡΠ΄ΠΊΠ΅ ΡΠ΅Π°Π»ΠΈΠ·ΠΎΠ²ΡΠ²Π°ΡΡΡΡ Π½Π° ΡΡΠΎΠ²Π½Π΅ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΡ
Π²ΡΠ·ΠΎΠ², ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΈΠΌ ΠΎΡΠ΅Π½ΠΈΡΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ²ΠΎΠ΅Π³ΠΎ Π²ΠΊΠ»Π°Π΄Π° Π² ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΡ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ². ΠΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΠ΅ Π² ΡΡΠ°ΡΡΠ΅ Π½ΠΎΠ²ΡΠ΅ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² Π² ΡΠ°ΡΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ² ΠΈ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠΈΡΡΠ΅ΠΌΡ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ³ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ ΠΎΡΠ³Π°Π½Π°ΠΌΠΈ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈ Π²ΡΠ·Π°ΠΌΠΈ Π΄Π»Ρ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠ΅Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΡΠΈΡΡΠ΅ΠΌΡ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ Π² ΡΠ΅Π»ΠΎΠΌ ΠΈ Π΅Π΅ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΡΠ»Π΅ΠΌΠ΅Π½ΡΠΎΠ²
Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3β6 months. Given the older median age of onsetΒ and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxicity. Ruxolitinib (a JAK1/2 inhibitor)Β has provided significant clinical benefits in patients with chronic phase myelofibrosis. We report our experience of treating blastphaseΒ myelofibrosis patients with the combination therapy of ruxolitinib plus low dose mercaptopurine or low-dose cytarabine. The casesΒ presented here demonstrated the feasibility and tolerability of combination continuous ruxolitinib treatment with mercaptopurine or low-doseΒ cytarabine for patients with blast-phase myelofibrosis. The efficacy of these combination regimens is encouraging